Genetic Medicines
Shaping the RNA Century
Powering the Promise of Oligonucleotide Medicines
Alloy Genetic Medicines is positioned to lead the RNA century, where AI-programmable sequences, precise delivery, potency, and patient safety define what’s possible. Our first RNA innovation ecosystem, the AntiClastic™ Cyclic RNA platform, converts linear RNAs and DNAs into IP-protected, configurable cyclic architectures, delivering nuclease-resistant therapeutics with greater potency, durability, specificity, and in vivo stability, while reducing immunostimulation.
ASO
Wide range
The Anticlastic™ Cyclic RNA Platform Is Manifesting the Promise of Oligonucleotide Therapeutics
Delivering Drug Candidates
The AntiClastic platform turns therapeutic concepts into IP-protected, clinic-ready assets by doing more than licensing technology: our labs design, build, test, and refine discovery candidates with you, from our AI/ML-enabled sequence conducted by our RNA Sequence Design Studio, through in vivo studies.
Transformative RNA Structures
Our novel, transiently cyclized RNAs, including ASOs, siRNAs, and sgRNAs, increase potency, stability, targeting precision, and durability, while reducing off-target RNA interactions and stimulating innate immunity. Proprietary AntiClastic cyclic architectures unlock modalities that achieve a range of functions for the genetic medicines toolbox.
Democratizing Access to RNA Innovation
We license our patented AntiClastic Cyclic RNA platform to pharmaceutical innovators, biotechs, and academic laboratories, partnering with you from discovery through clinical candidate selection—designing, building, testing, and refining discovery candidates with you, moving programs faster to the clinic with far less risk.
AntiClastic™ Cyclic RNA Platform
Patented AntiClastic Architectures Enable Wide-Ranging Applications
Developed in collaboration with Dr. Sudhir Agrawal, a pioneer in the antisense field, our proprietary AntiClastic cyclic architectures, such as ASOs, siRNAs, and sgRNAs, unlock modalities that enable a range of functions in genetic medicines, including targeted RNA degradation, splice modulation, gene editing and regulation, DNA modulation, ADAR editing, gene expression modulation, and more.
Improved Potency
The AntiClastic cyclic and 5’ end-engineering results in up to a 50-fold improvement in in vitro potency.
Increased Patient Safety
Reduced engagement of off-target RNA and pattern recognition receptors mitigates the inflammatory response, thereby improving the therapeutic index.
IP Protection
The AntiClastic platform creates novel, globally IP-protected therapeutic structures.
Clinically Validated Methods
Manufactured using conventional chemical methods and engineered with building blocks of clinically validated and established oligonucleotide therapeutic modifications.
We Don’t Just License Technology, We Deliver Drug Candidates
The AntiClastic Cyclic RNA platform transforms your therapeutic concepts into clinic-ready assets, not by merely licensing technology. We design, build, test, and refine discovery and development candidates with you.
Machine & human intelligence
Our AI/ML-enabled RNA Sequence Design Studio narrows hundreds of thousands of sequence options to a short list of high-potency screening candidates. Our expert scientists refine those outputs.
Lead identification
In vitro cell-based assays, using transfection, gymnosis, gene expression, off-target analysis, and biological safety evaluations.
Lead optimization & development
Improving leads across multiple parameters, including sequence selection, chemical modifications, in vivo and in vitro evaluation, efficacy, and safety profile.
Drug candidate nomination
Our comprehensive data packages enable confident selection of your lead and streamlined downstream development.
Genetic Medicines
Scientific Advisory Board
Sudhir Agrawal, D.Phil.
Founder ARNAY Sciences; Affiliate Professor, UMass Chan Medical School
Chair: Alloy Genetic Medicine SAB
Douglas Golenbock, M.D
Professor, UMass Chan Medical School
Neil and Margery Blacklow Chair in Infectious Diseases and Immunology
Malcolm MacCoss, PhD
Bohicket Pharma Consulting LLC
Visiting Professor of Chemistry for Medicine at University of Oxford,
Matthew Might, PhD
Professor, Dept. of Medicine Director, Hugh Kaul Precision Medicine Institute, The University of Alabama at Birmingham
Discuss partnering with Alloy
Learn how to get started with our proprietary AntiClastic ASO therapeutic formats.
Resources
